Menu Search
Equities

Revance Therapeutics Inc

RVNC:NMQ

Revance Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.86
  • Today's Change-0.13 / -2.17%
  • Shares traded1.55k
  • 1 Year change-57.57%
  • Beta0.9944
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Revance Therapeutics Inc grew revenues 76.55% from 132.57m to 234.04m while net income improved from a loss of 356.42m to a smaller loss of 323.99m.
Gross margin71.53%
Net profit margin-116.39%
Operating margin-112.58%
Return on assets-51.97%
Return on equity--
Return on investment-61.40%
More ▼

Cash flow in USDView more

In 2023, Revance Therapeutics Inc increased its cash reserves by 25.85%, or 29.73m. Cash Flow from Financing totalled 136.57m or 58.35% of revenues. In addition the company used 216.58m for operations while cash from investing totalled 109.74m.
Cash flow per share-3.00
Price/Cash flow per share--
Book value per share-1.24
Tangible book value per share-1.32
More ▼

Balance sheet in USDView more

Revance Therapeutics Inc has a Debt to Total Capital ratio of 140.73%, a lower figure than the previous year's 1,419.95%.
Current ratio3.74
Quick ratio3.01
Total debt/total equity--
Total debt/total capital1.41
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.